Show simple item record

dc.contributor.authordu Cros, Philipp; Atadjan, Khamraev; Mirzagalib, Tillashaikhov; Nargiza, Parpieva; Zinaida, Tigay; Marjan, Sholtaeva; Tleubergen, Abdrasuliev; Betlam, Marttje; Wise, Emily; Ashagre, Teshome; Kuhlin, Johanna; Slyzkyi, Andrii; Taye, Alia; Dietrich, Sebastian; Nyangwa, Bern-Thomas; Greig, Jane; Hepple, Pamela; Cooke, Graham; Herboczek, Krzysztof; Asif, Muhammad; Achar, Jay; Berry, Catherine
dc.date.accessioned2014-07-01T11:04:05Z
dc.date.available2014-07-01T11:04:05Z
dc.date.issued2014-07
dc.identifier.urihttp://hdl.handle.net/10144/322296
dc.descriptionResearch protocol. These materials can be used, adapted and copied as long as citation of the source is given including the direct URL to the material. This work is licensed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0/ https://i.creativecommons.org/l/by/4.0/88x31.pngen_GB
dc.description.abstractMultidrug resistant tuberculosis (MDR TB) is a growing problem and few people have access to adequate diagnosis and treatment. The current recommended treatment regimen for MDR TB has a minimum of 20 months duration with high toxicity. Scale up of MDR TB treatment is associated with high default rates, and experience in the MSF programme in Uzbekistan shows that the current standard treatment greatly limits the ability to scale up to meet the high rates of MDR TB in the region. A prospective observational study has been designed. The primary outcome measure is the success rate at the end of treatment, and relapse and re-infection rates during 12 months of follow up after completion of treatment. Secondary outcome measures include rate of adverse events, interim outcomes with sputum smear microscopy and culture conversion rates at 4 and 6 months and time to conversion. Primary objective: To describe outcomes at end of treatment and relapse rate at 1 year following treatment completion of a short course (9-11 month) MDR TB treatment in programmatic conditions in Karakalpakstan, Uzbekistan. Secondary objectives: 1. To describe the adverse events of the treatment regimen 2. To evaluate risk factors for unfavorable outcomes (death, lost-to-follow up and failure) and relapse as a combined cohort. 3. To describe the rate of resistance amplification amongst patients with outcome failure.
dc.language.isoenen
dc.subjectMDR TBen_GB
dc.subjecttreatmenten_GB
dc.titleResearch Protocol - Effectiveness of a simplified short regimen for Multidrug Resistant Tuberculosis treatment in Karakalpakstan, Uzbekistanen
dc.typeOtheren
dc.contributor.departmentMédecins Sans Frontières, Operational Center Amsterdam; Ministry of Health Uzbekistan; Ministry of Health Uzbekistan; Ministry of Health Uzbekistan; Ministry of Health Uzbekistan; Ministry of Health Uzbekistan; Ministry of Health Uzbekistan; Médecins Sans Frontières, Operational Center Amsterdam; Médecins Sans Frontières, Operational Center Amsterdam; Médecins Sans Frontières, Operational Center Amsterdam; Médecins Sans Frontières, Operational Center Amsterdam; Médecins Sans Frontières, Operational Center Amsterdam; Médecins Sans Frontières, Operational Center Amsterdam; Médecins Sans Frontières, Operational Center Amsterdam; Médecins Sans Frontières, Operational Center Amsterdam; Médecins Sans Frontières, Operational Center Amsterdam; Médecins Sans Frontières, Operational Center Amsterdam; Imperial College London; Médecins Sans Frontières, Operational Center Amsterdam; Médecins Sans Frontières, Operational Center Amsterdam; Médecins Sans Frontières, Operational Center Amsterdam; Médecins Sans Frontières, Operational Center Amsterdamen_GB
refterms.dateFOA2019-02-21T13:46:20Z
html.description.abstractMultidrug resistant tuberculosis (MDR TB) is a growing problem and few people have access to adequate diagnosis and treatment. The current recommended treatment regimen for MDR TB has a minimum of 20 months duration with high toxicity. Scale up of MDR TB treatment is associated with high default rates, and experience in the MSF programme in Uzbekistan shows that the current standard treatment greatly limits the ability to scale up to meet the high rates of MDR TB in the region. A prospective observational study has been designed. The primary outcome measure is the success rate at the end of treatment, and relapse and re-infection rates during 12 months of follow up after completion of treatment. Secondary outcome measures include rate of adverse events, interim outcomes with sputum smear microscopy and culture conversion rates at 4 and 6 months and time to conversion. Primary objective: To describe outcomes at end of treatment and relapse rate at 1 year following treatment completion of a short course (9-11 month) MDR TB treatment in programmatic conditions in Karakalpakstan, Uzbekistan. Secondary objectives: 1. To describe the adverse events of the treatment regimen 2. To evaluate risk factors for unfavorable outcomes (death, lost-to-follow up and failure) and relapse as a combined cohort. 3. To describe the rate of resistance amplification amongst patients with outcome failure.


Files in this item

Thumbnail
Name:
OCA013-11_MDR TB in Uzbekistan ...
Size:
413.5Kb
Format:
Microsoft Word
Description:
Research Protocol_ENGLISH
Thumbnail
Name:
Research Proposal v4.02 RUSSIAN.doc
Size:
380.5Kb
Format:
Microsoft Word
Description:
Research Protocol_RUSSIAN
Thumbnail
Name:
Annex 1 Clinical Protocol v4.02 ...
Size:
1.488Mb
Format:
Microsoft Word
Description:
Annex 1 - Clinical Protocol_ENGLISH
Thumbnail
Name:
Annex 1 Clinical Protocol v4.02 ...
Size:
1.511Mb
Format:
Microsoft Word
Description:
Annex 1 - Clinical Protocol_RUSSIAN
Thumbnail
Name:
Annex 2 Consent Form v4.00 ENG.docx
Size:
41.49Kb
Format:
Microsoft Word 2007
Description:
Annex 2 - Consent Form
Thumbnail
Name:
Annex 3 Side Effects Grading ...
Size:
64.5Kb
Format:
Microsoft Word
Description:
Annex 3 - Side Effects Grading
Thumbnail
Name:
Annex 4 EPI Forms v4.00 ENG.docx
Size:
162.7Kb
Format:
Microsoft Word 2007
Description:
Annex 4 - EPI Forms
Thumbnail
Name:
Annex 5 Pregnancy info v4.00 ...
Size:
52.28Kb
Format:
Microsoft Word 2007
Description:
Annex 5 - Pregnancy info
Thumbnail
Name:
Annex 6a Flipbook v4.00 ENG.doc
Size:
31.03Mb
Format:
Microsoft Word
Description:
Annex 6a - Flipbook
Thumbnail
Name:
Annex 6b PreTx Leaflet v4.00 ...
Size:
308Kb
Format:
Microsoft Word
Description:
Annex 6b - PreTx Leaflet
Thumbnail
Name:
Annex 7 DSMB TOR v4.00 ENG.docx
Size:
40.99Kb
Format:
Microsoft Word 2007
Description:
Annex 7 - DSMB TOR
Thumbnail
Name:
Annex 8 Checklist.doc
Size:
197Kb
Format:
Microsoft Word
Description:
Annex 8 - Checklist

This item appears in the following Collection(s)

Show simple item record